flumazenil has been researched along with gabapentin in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 11 (52.38) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Choi, Y; Raymer, BK | 1 |
| Porter, RJ | 1 |
| Paz, L; Peter, Y; Pick, CG; Toren, P; Weizman, R | 1 |
| Amsden, GW; Butler, TC; Rosen, RM; Wallace, AL | 1 |
| Baron, M; Gromov, I; Hanselka, LL; Urschel, HC; White, L | 1 |
| Anton, RF; Baros, AM; Latham, PK; Malcolm, R; Myrick, H; Randall, PK; Stewart, SH; Waid, R; Wright, TM | 1 |
| Baron, M; Hanselka, LL; Urschel, HC | 1 |
| Anton, RF; Baros, AM; Latham, PK; Myrick, H; Randall, PK; Schacht, JP; Waid, LR; Wright, TM | 1 |
| Annon, J; Bholat, MA; Charuvastra, C; Chim, D; Doraimani, G; Dowling, PT; Heinzerling, K; Hillhouse, M; Ling, W; Shoptaw, S | 1 |
| Anton, RF; Henderson, S; Li, X; Myrick, H; Randall, PK; Schacht, JP | 1 |
| Foti, C; Masciullo, M; Molinari, M; Pichiorri, F; Scivoletto, G | 1 |
2 review(s) available for flumazenil and gabapentin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Sleep modulating agents.
Topics: Animals; Humans; Sleep; Sleep Aids, Pharmaceutical; Sleep Wake Disorders; Wakefulness-Promoting Agents | 2019 |
5 trial(s) available for flumazenil and gabapentin
| Article | Year |
|---|---|
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.
Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug Therapy, Combination; Female; Flumazenil; GABA Modulators; Gabapentin; gamma-Aminobutyric Acid; Humans; Infusions, Intravenous; Logistic Models; Male; Medication Adherence; Middle Aged; Patient Selection; Sleep; Substance Withdrawal Syndrome; Temperance; Time Factors; Treatment Outcome | 2009 |
A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence.
Topics: Adolescent; Adult; Amines; Amphetamine-Related Disorders; Anticonvulsants; Behavior, Addictive; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug Therapy, Combination; Female; Flumazenil; GABA Modulators; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Patient Compliance | 2011 |
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Female; Flumazenil; Gabapentin; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Male; Middle Aged; Recurrence; Substance Withdrawal Syndrome; Treatment Outcome | 2011 |
Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence.
Topics: Adult; Amines; Amphetamine-Related Disorders; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug Combinations; Female; Flumazenil; GABA Modulators; Gabapentin; gamma-Aminobutyric Acid; Histamine Agonists; Humans; Hydroxyzine; Infusions, Intravenous; Male; Medication Adherence; Methamphetamine; Self Report | 2012 |
Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Brain; Cues; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Flumazenil; Follow-Up Studies; GABA Modulators; Gabapentin; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Secondary Prevention; Severity of Illness Index; Substance Withdrawal Syndrome; Treatment Outcome | 2013 |
14 other study(ies) available for flumazenil and gabapentin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Mechanisms of action of new antiepileptic drugs.
Topics: Acetamides; Acetates; Amines; Aminocaproates; Aminopyridines; Anti-Anxiety Agents; Anticonvulsants; Aspartic Acid; Benzodiazepines; Benzodiazepinones; Clobazam; Cyclohexanecarboxylic Acids; Dibenzocycloheptenes; Dizocilpine Maleate; Epilepsy; Felbamate; Flumazenil; GABA Antagonists; Gabapentin; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Imidazoles; Lamotrigine; Phenylcarbamates; Propylene Glycols; Receptors, GABA-A; Triazines; Vigabatrin | 1989 |
Behavioral effects of agents active at the gamma-aminobutyric acid receptor complex in the staircase paradigm.
Topics: Acetates; Adjuvants, Immunologic; Amines; Animals; Anti-Anxiety Agents; Anxiety; Azabicyclo Compounds; Behavior, Animal; Brain; Clonazepam; Cyclohexanecarboxylic Acids; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dose-Response Relationship, Drug; Exploratory Behavior; Flumazenil; GABA Modulators; Gabapentin; gamma-Aminobutyric Acid; Hypnotics and Sedatives; Male; Mice; Mice, Inbred ICR; Motor Activity; Neurons; Piperazines; Receptors, GABA-A | 2001 |
Flumazenil and dialysis for gabapentin-induced coma.
Topics: Acetates; Aged; Aged, 80 and over; Amines; Analgesics; Antidotes; Coma; Cyclohexanecarboxylic Acids; Flumazenil; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Phantom Limb; Renal Dialysis | 2003 |
Open-label study of a proprietary treatment program targeting type A gamma-aminobutyric acid receptor dysregulation in methamphetamine dependence.
Topics: Adolescent; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Female; Flumazenil; Gabapentin; gamma-Aminobutyric Acid; Humans; Hydroxyzine; Male; Methamphetamine; Middle Aged; Patient Dropouts; Prospective Studies; Receptors, GABA; Substance-Related Disorders | 2007 |
Flumazenil therapy for a gabapentin-induced coma: a case report.
Topics: Aged; Antidotes; Coma; Flumazenil; Gabapentin; Humans; Male; Quality of Life | 2021 |